Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Repligen Cp (RGEN)

Repligen Cp (RGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,850,036
  • Shares Outstanding, K 54,904
  • Annual Sales, $ 366,260 K
  • Annual Income, $ 59,930 K
  • 60-Month Beta 0.90
  • Price/Sales 44.95
  • Price/Cash Flow 121.04
  • Price/Book 10.02
Trade RGEN with:

Options Overview

Details
  • Implied Volatility 39.14%
  • Historical Volatility 15.89%
  • IV Percentile 33%
  • IV Rank 31.82%
  • IV High 58.06% on 10/30/20
  • IV Low 30.32% on 07/27/21
  • Put/Call Vol Ratio 2.53
  • Today's Volume 173
  • Volume Avg (30-Day) 175
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 746
  • Open Int (30-Day) 959

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.64
  • Number of Estimates 6
  • High Estimate 0.66
  • Low Estimate 0.62
  • Prior Year 0.40
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
262.63 +16.53%
on 08/23/21
311.29 -1.68%
on 09/20/21
+43.36 (+16.51%)
since 08/20/21
3-Month
189.19 +61.77%
on 06/25/21
311.29 -1.68%
on 09/20/21
+108.71 (+55.09%)
since 06/18/21
52-Week
138.00 +121.78%
on 09/24/20
311.29 -1.68%
on 09/20/21
+160.06 (+109.64%)
since 09/18/20

Most Recent Stories

More News
Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study

Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.

REGN : 640.89 (-1.69%)
BIIB : 298.49 (-0.57%)
VRTX : 185.67 (-1.40%)
RGEN : 306.05 (-0.28%)
Repligen Announces Agreement to Acquire Avitide Inc.

-- Adds a market leader in affinity ligand discovery and development and complements established partnership with Navigo GmbH

RGEN : 306.05 (-0.28%)
aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923

aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.

REGN : 640.89 (-1.69%)
LIFE : 10.22 (-0.87%)
MRNA : 423.33 (-1.56%)
RGEN : 306.05 (-0.28%)
BOLT Enters Into a Collaboration Agreement With Bristol Myers

BOLT collaborates with Bristol Myers to investigate its pipeline candidate BDC-1001 in combination with the latter???s Opdivo.

REGN : 640.89 (-1.69%)
BMY : 60.50 (-1.32%)
RGEN : 306.05 (-0.28%)
BOLT : 13.96 (-8.70%)
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH ("Navigo"), today...

RGEN : 306.05 (-0.28%)
Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED

Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.

REGN : 640.89 (-1.69%)
IRWD : 12.35 (unch)
HZNP : 108.02 (-1.54%)
RGEN : 306.05 (-0.28%)
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis

Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.

REGN : 640.89 (-1.69%)
IRWD : 12.35 (unch)
RGEN : 306.05 (-0.28%)
RDHL : 4.55 (-6.95%)
Supernus (SUPN) Seeks Label Expansion for ADHD Drug Qelbree

The FDA accepts Supernus' (SUPN) regulatory application seeking label application for Qelbree to include adult patients with ADHD.

JNJ : 163.81 (-0.57%)
RGEN : 306.05 (-0.28%)
SUPN : 26.82 (-1.69%)
TAK : 17.06 (-0.52%)
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study

Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.

RHHBY : 45.5700 (-1.09%)
IRWD : 12.35 (unch)
RGEN : 306.05 (-0.28%)
TAK : 17.06 (-0.52%)
Roche (RHHBY) Withdraws Tecentriq for Breast Cancer in the U.S.

Roche (RHHBY) will withdraw Tecentriq for treating adults with unresectable locally advanced or metastatic triple-negative breast cancer in the United States.

RHHBY : 45.5700 (-1.09%)
BMY : 60.50 (-1.32%)
MRK : 71.93 (+0.35%)
RGEN : 306.05 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide....

See More

Key Turning Points

3rd Resistance Point 325.93
2nd Resistance Point 318.61
1st Resistance Point 312.33
Last Price 306.05
1st Support Level 298.73
2nd Support Level 291.41
3rd Support Level 285.13

See More

52-Week High 311.29
Last Price 306.05
Fibonacci 61.8% 245.09
Fibonacci 50% 224.65
Fibonacci 38.2% 204.20
52-Week Low 138.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar